BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, June 14, 2026
Home » Topics » Medical technology

Medical technology
Medical technology RSS Feed RSS

J.P. Morgan Healthcare & OneMedForum 2012 Conferences: Diagnostic companies display wares to highly receptive audience

Jan. 11, 2012
By Holland Johnson
SAN FRANCISCO Just a couple of blocks away from the shoulder-to-shoulder crowds at the J.P. Morgan Healthcare Conference, the much smaller OneMedForum conference on healthcare was moving along at the Sir Francis Drake Hotel. A Tuesday morning track on diagnostics held attendees in thrall, with several intriguing private companies vying for the affections, and potentially, funding from investors. (Medical Device Daily)
Read More
Uspstf101sl8

The policy dilemma of prostate cancer screening

Jan. 10, 2012
By Mark McCarty
  Screening for various diseases is controversial these days thanks to the U.S. Public Services Task Force and similar agencies in other nations, which have suggested a more cautious approach to screening. These suggestions have been blasted by doctors and patient groups for obvious reasons. Former Medical Device Daily executive editor Jim Stommen took up prostate cancer screening in a posting at this blog a few weeks back, and while I agree with Jim on a lot of things, I felt one perspective was missing; that of the federal budget. The problem is that no national economy can support indiscriminate...
Read More

People in the News

Jan. 10, 2012

Court report: Transgenomic, Power3 in agreement to end litigation

Jan. 10, 2012

Product Briefs

Jan. 10, 2012

Restructuring roundup: Conceptus reduces field sales workforce by 15%

Jan. 10, 2012

MDD's Cardio Extra

Jan. 10, 2012

J.P. Morgan Healthcare 2012 Conference: Healthcare sector still shows promise despite tough '11

Jan. 10, 2012
By Holland Johnson
SAN FRANCISCO − Early arrivals to this year's addition of the J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel were treated to something that would soon be in short supply . . . elbow room. This reporter was certainly envious when Managing Director Kevin Willsey noted that the first meeting back in 1983 had less than 100 attendees. This year's addition of what is arguably the preeminent conference in the healthcare sector had more than 8,500 registered attendees. (Medical Device Daily)
Read More

Pathwork study shows test can impact cancer treatment

Jan. 10, 2012
By Omar Ford

Medtronic CEO: 'business model has to be adjusted'

Jan. 10, 2012
By Amanda Pedersen
Previous 1 2 … 3974 3975 3976 3977 3978 3979 3980 3981 3982 … 10250 10251 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 12, 2026.
  • Purple molecules

    Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis

    BioWorld
    Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
  • Neck exam

    Ethyreal launches to treat the underlying cause of Graves’, TED

    BioWorld
    Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
  • 3D illustration of a nerve cell

    Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?

    BioWorld
    Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
  • Illustration of Lactobacillus

    Microbiota modulates the antidepressant effects of GLP-1 analogues

    BioWorld Science
    Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing